Medicus Pharma’s (MDCX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a research note published on Monday,Benzinga reports. The brokerage currently has a $14.00 price target on the stock.

Separately, D Boral Capital raised Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th.

Medicus Pharma Price Performance

Shares of MDCX opened at $4.20 on Monday. The firm’s fifty day moving average price is $3.59. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.14. As a group, equities research analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th biggest position. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent SEC filing.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.